NASDAQ · Financial Statements

Enanta Pharmaceuticals, Inc. (ENTA) Financial Statements

$11.64 NASDAQ: ENTA Market Cap $339.02M

Enanta Pharmaceuticals, Inc. most recently reported annual revenue of $65.0M, a net loss of $82.0M. Revenue declined at an average annual rate of 11.8% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Enanta Pharmaceuticals, Inc.: Revenue fell from $88.0M in 2016 to $65.0M in 2025, a change of -26.1% over 9 years; net profit was positive in 4 of 10 reported years; operating margin moved from 34.9% to -130.7%, a shift of -165.6 percentage points; the most recent year shows a net loss of $82.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$88.0M$103.0M$207.0M$205.0M$122.0M$97.0M$86.0M$79.0M$68.0M$65.0M
Operating Expenses$57.0M$78.0M$118.0M$168.0M$164.0M$207.0M$210.0M$216.0M$189.0M$151.0M
Operating Profit$31.0M$25.0M$88.0M$37.0M$-42.0M$-110.0M$-124.0M$-137.0M$-122.0M$-85.0M
Operating Margin34.9%23.9%42.8%17.9%-34.0%-112.9%-143.7%-173.2%-179.9%-130.7%
Other Income$2.0M$2.0M$5.0M$9.0M$7.0M$2.0M$2.0M$6.0M$4.0M$2.0M
Interest$0$0$5.0M$0$0$0$0$5.0M$11.0M$8.0M
Depreciation$2.0M$2.0M$3.0M$3.0M$4.0M$3.0M$3.0M$2.0M$2.0M$5.0M
Profit Before Tax$33.0M$27.0M$93.0M$46.0M$-35.0M$-108.0M$-122.0M$-131.0M$-118.0M$-84.0M
Tax$33.5M$34.3M$22.7M$-1.8M$-3.3M$26.6M$350,000$-2.1M$1.5M$2.0M
Net Profit$22.0M$18.0M$72.0M$46.0M$-36.0M$-79.0M$-122.0M$-134.0M$-116.0M$-82.0M
EPS$1.13$0.91$3.48$2.21$-1.81$-3.92$-5.91$-6.38$-5.48$-3.84
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$19.0M$18.0M$17.0M$18.0M$15.0M$17.0M$15.0M$18.0M$15.0M$19.0M$17.0M$14.0M
Operating Expenses$50.0M$53.0M$50.0M$42.0M$44.0M$41.0M$39.0M$37.0M$34.0M$30.0M$29.0M$32.0M
Operating Profit$-31.0M$-35.0M$-33.0M$-24.0M$-30.0M$-24.0M$-25.0M$-19.0M$-18.0M$-11.0M$-12.0M$-17.0M
Operating Margin-163.9%-193.8%-192.1%-134.6%-204.4%-138.8%-164.3%-103.2%-121.6%-60.5%-69.1%-120.0%
Interest$3.0M$3.0M$3.0M$2.0M$3.0M$2.0M$2.0M$2.0M$2.0M$3.0M$3.0M$4.0M
Profit Before Tax$-30.0M$-34.0M$-32.0M$-23.0M$-29.0M$-23.0M$-24.0M$-18.0M$-19.0M$-12.0M$-13.0M$-19.0M
Tax$4.8M$1.8M$1.1M$1.7M$1.2M$1.8M$5.5M$-160,000$-170,000$-200,000$-50,000$-180,000
Net Profit$-28.0M$-33.0M$-31.0M$-23.0M$-29.0M$-22.0M$-23.0M$-18.0M$-19.0M$-12.0M$-13.0M$-20.0M
EPS$-1.33$-1.58$-1.47$-1.07$-1.36$-1.05$-1.06$-0.86$-0.87$-0.42$-0.45$-0.67

Over the 10 years reported for Enanta Pharmaceuticals, Inc., borrowings increased from $1.0M in 2016 to $201.0M in 2025, cash stood at $32.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 4.16 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$281.0M$327.0M$414.0M$490.0M$491.0M$441.0M$381.0M$462.0M$377.0M$281.0M
Current Assets$232.0M$238.0M$380.0M$402.0M$437.0M$319.0M$312.0M$423.0M$300.0M$204.0M
Cash$17.0M$66.0M$64.0M$51.0M$87.0M$57.0M$44.0M$85.0M$37.0M$32.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$13.0M$11.0M$67.0M$51.0M$23.0M$61.0M$49.0M$40.0M$39.0M$7.0M
Fixed Assets$8.0M$8.0M$8.0M$11.0M$16.0M$11.0M$30.0M$35.0M$73.0M$73.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$226.0M$228.0M$261.0M$349.0M$333.0M$296.0M$238.0M$288.0M$214.0M$160.0M
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$11.0M$25.0M$21.0M$27.0M$35.0M$41.0M$59.0M$246.0M$248.0M$216.0M
Current Liabilities$8.0M$21.0M$16.0M$23.0M$24.0M$36.0M$30.0M$63.0M$58.0M$49.0M
Borrowings$1.0M$0$0$0$10.0M$7.0M$27.0M$27.0M$226.0M$201.0M
Other Liabilities$11.0M$25.0M$20.0M$27.0M$26.0M$35.0M$33.0M$219.0M$22.0M$15.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$270.0M$302.0M$394.0M$462.0M$456.0M$399.0M$321.0M$217.0M$129.0M$65.0M

For Enanta Pharmaceuticals, Inc., operating cash flow was positive in 5 of 10 reported years; free cash flow in the latest year was negative at $32.0M; free cash flow was positive in 5 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$36.0M$53.0M$29.0M$71.0M$7.0M$-70.0M$-85.0M$-103.0M$-79.0M$-19.0M
Investing Cash Flow$-87.0M$-9.0M$-71.0M$-5.0M$18.0M$36.0M$53.0M$-63.0M$40.0M$27.0M
Financing Cash Flow$3.0M$1.0M$4.0M$3.0M$9.0M$-1.0M$-1.0M$-4.0M$0$0
Net Cash Flow$-5.0M$49.0M$-2.0M$-13.0M$36.0M$-30.0M$-10.0M$41.0M$-48.0M$-6.0M
Free Cash Flow$31.0M$50.0M$26.0M$66.0M$6.0M$-71.0M$-87.0M$-112.0M$-97.0M$-32.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.08
EV / EBITDA-8.49
FCF Yield-9.91%
Quick Ratio3.76
Interest Coverage-4.55
Return 1Y67.53%
Return 3Y-29.73%
Return 5Y-68.86%

Enanta Pharmaceuticals, Inc. (ENTA) financials — frequently asked questions

What is Enanta Pharmaceuticals, Inc.'s annual revenue?

Enanta Pharmaceuticals, Inc. (ENTA) reported annual revenue of $65.0M in its most recent fiscal year.

What is Enanta Pharmaceuticals, Inc.'s net profit?

Enanta Pharmaceuticals, Inc. (ENTA) reported a net loss of $82.0M in its most recent fiscal year.

What is ENTA EV/EBITDA?

Enanta Pharmaceuticals, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -8.49. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
ENTA Overview ENTA Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.